NKTX
NkartaANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bull case is that Nkarta now has a clearer runway into 2029, which lowers near-term financing pressure and gives management time to reach the first Ntrust-1/Ntrust-2 efficacy data in 2026. If the initial dataset is clean, the stock has room to rerate from a very low base.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +0.8.
What can break
No efficacy readout has been disclosed yet for Ntrust-1 or Ntrust-2, so the main thesis remains unproven.
Momentum
88
Value
58
Sentiment
43
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.75 · Bull $5.50 · Bear $1.15
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-19 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $11.80
Why
Momentum88 · Δ7d +0.8
Value58 · Δ7d +0.3
Sentiment43 · Δ7d -2.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
88
34% active weight
Current posture
7d trendImproving
Δ7d
+0.8
Δ21d
-4.2
Value
58
32% active weight
Current posture
7d trendFlat
Δ7d
+0.3
Δ21d
+0.1
Sentiment
43
33% active weight
Current posture
7d trendSoftening
Δ7d
-2.4
Δ21d
-13.4
Why this grade
Composite grade A. Momentum 88.1 / Value 58.0 / Sentiment 42.8
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$224.65M
Beta
0.55
Shares Out
71.03M
P/E (TTM) · Derived
-2.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.50
Rev YoY
-
EPS YoY
+23.9%
Gross Margin
-
Op Margin
-
Net Debt
-$267.35M
Current Ratio
15.23
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology